Home Our Team Faculty L. Charles Bailey, MD, PhD Profile

L. Charles Bailey, MD, PhD

L. Charles Bailey, MD, PhD

Attending physician
Assistant professor of pediatrics, University of Pennsylvania School of Medicine

Contact L. Charles Bailey, MD, PhD

View L. Charles Bailey's Laboratory

Resume

ERROR_FILE
    • Primary Address:
      Hospital of the University of Pennsylvania
      Cardiovascular Medicine Division
      3400 Spruce St.
      9018 Gates Pavilion
      Philadelphia, PA 19104
    • (215) 662-2285

      Expertise

      CVI:

      Director, Noninvasive Imaging

      CVI Program Unit(s):
      Cardiovascular Development / Congenital Heart Disease
      Biotechnology / Nanomedicine / Imaging

      CVI Research Description:
      My longstanding interests is in using cardiovascular imaging to investigate left ventricular remodeling. This has involved using Doppler echocardiography in large clinical trials accessing the efficacy of pharmaceutical interventions (ACE inhibitors and beta blockers post infarction) and the role of devices including epicardial and endocardial restraint. More recently I am studying the role of cardiac resynchronization and reverse remodeling with advanced heart failure (MIRACLE, MIRACLE ICD, BLOCK-HF and REVERSE Trials).

      I also direct the quantitative echocardiographic core laboratory in a number of additional clinical trials that have involved quantitative imaging.

      ITMAT:

      Dr. Fisher is interested in the management of brain tumors and tumors related to neurofibromatosis type 1 and in new imaging modalities for evaluation of plexiform neurofibromas and brain tumors.

      Appointments

      • Associate Professor of Pediatrics at the Children's Hospital of Philadelphia (2012 – present)
      • Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (2003 – 2012)
      • John W. Bryfogle Professor of Medicine, University of Pennsylvania School of Medicine (1993 – present)
      • Assistant Professor of Medicine, University of Pennsylvania School of Medicine (1980 – 1984)

      Education

      • M.D., Harvard Medical School (cum Laude) (1994)
      • FRCP, Royal College of Physicians, London, UK (1993)
      • FESC, Fellow of the European Society of Cardiology (1991)
      • B.A., Psychology, Summa cum Laude, Amherst College (1989)
      • FACC, American College of Cardiology (1984)
      • MRCP, Royal College of Physicians, London, UK (1973)
      • MBBS, Guys Hospital Medical School, London, UK (1970)
      • BSc, Guys Hospital Medical School, London, UK (1967)

      Extended Bio

      I am part of the Hematologic Malignancies group at Children's Hospital, which focuses on the care of children with leukemia, lymphoma and related diseases. My particular clinical focus is on acute lymphoblastic leukemia, the most common type of childhood cancer. My goal, along with my colleagues, is to provide the best possible care for children with cancer, whether at initial diagnosis or when relapse or problems with treatment occur. This means making available treatments that are based on current research as well as established standards.

      In addition to having medical expertise, it’s also important to provide compassionate and responsive care for patients and their families--at times which can be very stress-filled and confusing. Part of my role is to insure that families are well-informed about the treatment their child receives and are comfortable with the choices they make. This helps ensure they can participate as an active part of the care team. It extends to treatment decisions as well as to supporting quality of life and normal development despite medical needs. To develop better ways to cure cancer in children, we need to learn more about how leukemias and lymphomas behave--often referred to as disease biology--and about the actual effectiveness and risks of different treatment strategies for patients. This area includes both clinical trials and outcomes research.

      My background is in biomedical informatics, which is the use of information technology and computer science to answer questions about medicine, ranging from molecular biology to quality of care. I strongly believe it's possible to improve clinical care by gathering more appropriate information and providing better ways to organize that information for the clinicians making patient decisions. My research focuses on different aspects of this question. I am part of the team at Children's Hospital working to develop the Pediatric Electronic Data Sharing Network (PEDSNet). This collaboration among children’s hospitals is dedicated to using information from electronic medical records to perform more accurate outcomes and quality research than is possible using currently available information. I am also working with a multi-specialty group at Children's Hospital to develop new ways to collect medical information and present it to clinicians at the time of a clinic visit to enable them to make better decisions about patient care.

      There is a practical dimension to medical informatics as well. To make well-informed decisions, clinicians must be able to: gather accurate information; have organized ways to look at whether current practice is safe and effective and how it could be improved; and must have tools to provide the right information when decisions are being made. To help achieve these goals at Children's Hospital, I have committed a significant part of my work to building the Epic electronic health record for care of oncology patients and other acutely ill children at CHOP.

      I also serve on the oncology quality improvement and clinical care committees, co-chair the chemotherapy safety committee and represent our group on Children's Hospital’s bloodstream infection steering group and the NACHRI hematology/oncology collaborative for reducing bloodstream infections. Each of these groups is committed to making care of children safer and more reliable. We are finding ways to reduce harm to patients--both errors and side effects of treatment--and improve adoption of practices that have been shown to be more effective.

      One of the phrases we use to describe our commitment to our patients is “caring for your child like I would care for my own child.” This sets a high standard, but I believe we would not be justified in seeking anything less. My hope is that through this combination of clinical, research and administrative work I can help to maintain pediatric care for children, not only here at Children's Hospital but elsewhere--at a level I would be happy for my family to receive.

      Publications

      • Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG. Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.. Pediatric Blood & Cancer. In Press.
      • Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatric Blood & Cancer. Vol 60(5) . 2013 September:776-782.
      • de Blank PMK, Berman JI, Liu GT, Roberts TP, Fisher MJ. Fractional Anisotropy of the Optic Radiations is Associated with Visual Acuity Loss in Optic Pathway Gliomas of Neurofibromatosis Type 1.. Neuro-Oncol. Vol 15(8) . 2013 August:1088-95.
      • Scott JR, Courter JD, Saldaa SN, Widemann BC, Fisher M, Weiss B, Perentesis J, Vinks AA. Population Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1.. Ther Drug Monit. Vol 35(3) . 2013 June:332-337.
      • Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC. Achieving Consensus for Clinical Trials: the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.. Neurology. Vol 81((Suppl 1)) . 2013:S1?S5.
      • Liu GT, Katowitz JA, Rorke-Adams LB, Fisher MJ. Optic Pathway Gliomas: Neoplasms, not Hamartomas.. JAMA Ophthalmology. Vol 131(5) . 2013:646-650.
      • Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE, Gutmann DH, Listernick R, Martin S, Ullrich NJ, Liu GT, for the REiNS International Collaboration. Functional outcome measures for NF1-Associated Optic Pathway Glioma Clinical Trials.. Neurology. Vol 81((Suppl 1)) . 2013:S15?S24.
      • Widemann BC, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Plotkin SR. Future Directions for the REiNS International Consortium.. Neurology. Vol 81((Suppl 1)) . 2013:S41?S44.
      • Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih C-S, Widemann BC, for the REiNS International Collaboration. Recommendations for Imaging Tumor Response in Neurofibromatosis Clinical Trials.. Neurology. Vol 81((Suppl 1)) . 2013:S33?S40.
      • Kranick SM, Campen CJ, Kasner SE, Kessler SK, Zimmerman RA, Lustig RA, Phillips PC, Beslow LA, Ichord R, Fisher MJ. Headache as a Risk Factor for Neurovascular Events in Pediatric Brain Tumor Patients. Neurology. Vol 80(16) . 2013:1452-1456.